Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer

Last updated: May 6, 2024
Sponsor: Universita di Verona
Overall Status: Completed

Phase

N/A

Condition

Neoplasms

Treatment

N/A

Clinical Study ID

NCT03788382
FOUNTAIN
  • Ages > 18
  • All Genders

Study Summary

This study aims to evaluate the rate of patients submitted to pancreatic resection for pancreatic cancer, who fail to access to adjuvant therapy or do not complete adjuvant therapy. The purpose is to give an overview concerning the most frequent conditions and/or reasons associated with failure or omission of adjuvant therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologic diagnosis of pancreatic cancer

Exclusion

Exclusion Criteria:

  • Non exocrine pancreatic tumors
  • Periampullary malignancies

Study Design

Total Participants: 317
Study Start date:
January 01, 2019
Estimated Completion Date:
February 28, 2024

Study Description

This prospective observational study will evaluate all patients submitted to pancreatic resection for pancreatic cancer.

The rate of omission to adjuvant therapy and rate of failure of completion of adjuvant therapy will be evaluated as primary outcomes. As secondary outcomes, survival analyses will be performed to investigate whether these factors influence prognosis, that will be evaluated through a disease free survival analysis at 18-months. Epidemiological and perioperative data will be analyzed to identify conditions associated with the primary outcomes.

Connect with a study center

  • University of Verona Hospital

    Verona, 37134
    Italy

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.